Skip to main content

Table 4 Urinary biomarkers data of the studied population represented as means± standard deviation (lower limit- upper limit)

From: Urinary biomarkers for early detection of platinum based drugs induced nephrotoxicity

Biomarkers (ng/ml)

AKI (+) 35 cases

AKI (−) 97 cases

p-value

1. KIM-1

 Day 0

1.04 ± 0.2 (0.84–1.24)

1.2 ± 0.21 (0.99–1.41)

0.39

 Day 1

1.5 ± 0.2 (1.3–1.7)

1.3 ± 0.2 (1.1–1.5)

0.62

 Day 2

2.1 ± 0.19 (1.91–2.29)

1.2 ± 0.27 (0.93–1.47)

0.0092**

 Day 3

2.25 ± 0.18 (2.07–2.43)

1.4 ± 0.2 (1.2–1.6)

0.0054**

2. NGAL

 Day 0

416 ± 46.7 (369.3–462.7)

413 ± 49.6 (363.4–462.6)

0.92

 Day 1

426.3 ± 52.34 (373.69–478.64)

419.2 ± 58.4 (360.8–477.6)

0.92

 Day 2

573.2 ± 39.24 (533.69–612.44)

422.8 ± 38.3 (384.5–461.1)

0.0032**

 Day 3

611.6 ± 46.35 (565.25–657.95)

420.8 ± 42.3 (478.5–463.1)

0.0088**

3. Cys-c

 Day 0

14.5 ± 1.49 (13.01–15.99)

12.48 ± 1.42 (11.06–13.9)

0.22

 Day 1

15.6 ± 1.7 (13.9–17.3)

12.9 ± 1.1 (11.8–14)

0.12

 Day 2

18.6 ± 1.9 (16.7–20.5)

13.26 ± 0.68 (12.58–13.94)

0.013*

 Day 3

22.1 ± 2.28 (19.82–24.38)

13.44 ± 0.53 (12.9–13.97)

0.003**

  1. Day 0 means the day of PBD intake. Day 1, day2 and day3 means one, two and three days after PBD intake
  2. * means p< .05, ** means p< .01